11 May
2022
11 May
'22
10:12 p.m.
Is dit iets dat we doorsturen?
Is afkomstig van EAHP maar wel gesponsord door Bayer.
---
Met vriendelijke groeten,
Mailboxteam
Secretariaat VZA
Vlaamse Vereniging van Ziekenhuisapothekers
vzw erkend als beroepsvereniging | BE 0476.978.494 | RPR, afdeling Gent
VZA (t.a.v. UZG apotheek) | C. Heymanslaan 10 | 9000 Gent
secretariaat(a)vza.be | www.vza.be [1]
-------- Oorspronkelijke bericht --------
ONDERWERP:
Webinar Finerenone - Treatment option for CKD in patients with T2DM
DATUM:
2022-05-11 14:41
AFZENDER:
advertisement <advertisements(a)eahp.eu>
ONTVANGER:
secretariaat(a)vza.be
ANTWOORD-AAN:
advertisements(a)eahp.eu
Finerenone Webinar
A new treatment option with a positive benefit-risk profile for Chronic
Kidney Disease (CKD; stage 3 and 4 with albuminuria) in patients with
Type 2 Diabetes (T2DM)
Finerenone is a new, selective, nonsteroidal mineralocorticoid receptor
agonist (MRA) that is different from available steroidal MRAs. This
webinar explores how T2DM affects the development of CKD and how
finerenone could impact the treatment management in this patient
population. Current guidelines recommend a combination of therapies to
reduce the risk of CKD in T2DM1-7. Yet, even then a residual risk of
cardio-renal events remains high in affected patients8-13. In patients
with CKD and T2D, treatment with finerenone resulted in lower risks of
CKD progression and cardiovascular events than placebo5,6.
1. National Kidney Foundation. _Am J Kidney Dis_ 2007;49(suppl
2):S1-S180; 2. National Kidney Foundation. _Am _
_J Kidney Dis_ 2012;60:850-886; 3. Kidney Disease Improving Global
Outcomes. _Kidney Int Suppl _2020;98:S1-S115; 4. Kidney Disease
Improving Global Outcomes Blood Pressure Work Group. _Kidney Int Suppl
_2021;99:S1-S87; 5. American Diabetes Association. _Diabetes Care
_2022;45(Suppl 1):S175; 6. American Diabetes Association. _Diabetes
Care_ 2022;45(Suppl 1):S4; 7. Cosentino F, _et al. Eur Heart J
_2019;40:3215-3217; 8.Brenner BM, _et al._
_N Engl J Med _2001;345:861-869; 9. Lewis EJ, _et al. N Engl J Med
_2001;345:851-860; 10. Perkovic V, _et al. N _
_Engl J Med_ 2019;380:2295-2306; 11. Heerspink HJL, _et al. Lancet
_2019;393:1937-1947; 12. Bakris GL, e_t al. Am. J. Nephrol.
_2019;50:333-44. 13. Bakris GL _et al. NEMJ _2020;383:2219-29
Learning objectives
At the end of the webinar, participants will be able to:
* Describe the need for a new therapeutic option in eligible patients
with Type 2 Diabetes and Chronic Kidney disease
* Understand the clinical studies that were conducted with finerenone
* Be able to initiate finerenone taking serum potassium and the
estimated
glomerular filtration rate into consideration
* Counsel patients and HCPs regarding the efficacy and tolerability of
finerenone in
a hospital and community setting
Webinar sessions
Register here to receive your Zoom link to attend the webinar
Tuesday, 17 May 2022 19:00 H to 20:30 H CET
REGISTER FOR MAY 17
Speakers
Ina Richling, PharmD (UFl, USA)
Renal pharmacist
Katholische Kliniken im Märkischen Kreis, Germany
Lorenz Van der Linden, PharmD, PhD
Hospital pharmacy department
UZ Leuven, Belgium
This webinar is funded and developed by Bayer.
MA-M_FIN-ALL-0737
Registration
Pharmabrain GmbH, Berlin
Invitation
EAHP, Brussels
Unsubscribe [2] - Unsubscribe Preferences [3]
Links:
------
[1] http://www.vza.be/
[2]
http://mailinglinks.eahp.eu/asm/unsubscribe/?user_id=7164162&data=O…
[3]
http://mailinglinks.eahp.eu/asm/?user_id=7164162&data=3RPEqJj5mUhuX…
